115 related articles for article (PubMed ID: 1641157)
1. Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis.
Freedman MS; Muth KL; Trotter JL; Yoshizawa CN; Antel JP
Neurology; 1992 Aug; 42(8):1596-601. PubMed ID: 1641157
[TBL] [Abstract][Full Text] [Related]
2. Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility.
Peter JB; Boctor FN; Tourtellotte WW
Neurology; 1991 Jan; 41(1):121-3. PubMed ID: 1985276
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.
Ott M; Demisch L; Engelhardt W; Fischer PA
J Neurol; 1993 Dec; 241(2):108-14. PubMed ID: 8138825
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls.
Sivieri S; Ferrarini AM; Gallo P
Mult Scler; 1998 Feb; 4(1):7-11. PubMed ID: 9532585
[TBL] [Abstract][Full Text] [Related]
5. The relationship of interleukin-2 and soluble interleukin-2 receptors to intrathecal immunoglobulin synthesis in patients with multiple sclerosis.
Sharief MK; Hentges R; Thompson EJ
J Neuroimmunol; 1991 Apr; 32(1):43-51. PubMed ID: 2002090
[TBL] [Abstract][Full Text] [Related]
6. Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.
Sharief MK; Thompson EJ
J Neurol Neurosurg Psychiatry; 1993 Feb; 56(2):169-74. PubMed ID: 8437006
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: effect of interferon therapy.
Simsek H; Kadayifci A
J Int Med Res; 1996; 24(3):239-45. PubMed ID: 8725984
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid levels of myelin basic protein-like material and soluble interleukin-2 receptor in multiple sclerosis.
Fesenmeier JT; Whitaker JN; Herman PK; Walker DP
J Neuroimmunol; 1991 Oct; 34(1):77-80. PubMed ID: 1716642
[TBL] [Abstract][Full Text] [Related]
9. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission.
Van Kemseke C; Belaiche J; Louis E
Int J Colorectal Dis; 2000 Aug; 15(4):206-10. PubMed ID: 11008719
[TBL] [Abstract][Full Text] [Related]
10. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid.
Gallo P; Piccinno MG; Pagni S; Argentiero V; Giometto B; Bozza F; Tavolato B
J Neurol Sci; 1989 Aug; 92(1):9-15. PubMed ID: 2504888
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
Shaarawy M; Darwish NA; Abdel-Aziz O
J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
[TBL] [Abstract][Full Text] [Related]
12. [Clinical course and changes of soluble interleukin-2 receptor and soluble forms of intercellular adhesion molecule-1 (ICAM-1) in serum of multiple sclerosis patients].
Bilińska M; Frydecka I; Podemski R
Neurol Neurochir Pol; 2001; 35(1):47-56. PubMed ID: 11464716
[TBL] [Abstract][Full Text] [Related]
13. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
[TBL] [Abstract][Full Text] [Related]
14. IL-2 regulation of soluble IL-2 receptor levels following thermal injury.
Teodorczyk-Injeyan JA; Sparkes BG; Lalani S; Peters WJ; Mills GB
Clin Exp Immunol; 1992 Oct; 90(1):36-42. PubMed ID: 1382903
[TBL] [Abstract][Full Text] [Related]
15. Soluble serum interleukin 2 receptors in patients with systemic sclerosis.
Steen VD; Engel EE; Charley MR; Medsger TA
J Rheumatol; 1996 Apr; 23(4):646-9. PubMed ID: 8730120
[TBL] [Abstract][Full Text] [Related]
16. In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.
Sharief MK; Hentges R; Ciardi M; Thompson EJ
J Neurol; 1993 Jan; 240(1):46-50. PubMed ID: 8423463
[TBL] [Abstract][Full Text] [Related]
17. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition.
Symons JA; Wood NC; Di Giovine FS; Duff GW
J Immunol; 1988 Oct; 141(8):2612-8. PubMed ID: 3262665
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum.
Gallo P; Piccinno MG; Tavolato B; Sidén A
J Neurol Sci; 1991 Feb; 101(2):227-32. PubMed ID: 1827837
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-2 receptor as a marker of lymphocyte activation in childhood Crohn's disease.
Proujansky R; Carpenter AB
J Pediatr Gastroenterol Nutr; 1991 Oct; 13(3):277-84. PubMed ID: 1791504
[TBL] [Abstract][Full Text] [Related]
20. Inability of isolated soluble interleukin-2 receptor levels to predict biopsy rejection scores after heart transplantation.
Young JB; Windsor NT; Smart FW; Kleiman NS; Weilbaecher DG; Noon GP; Nelson DL; Lawrence EC
Transplantation; 1991 Mar; 51(3):636-41. PubMed ID: 2006520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
